WatersWAT
Recorded

Waters 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 1 minParticipants11

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to the Waters Corporation Third Quarter 2026 Financial Results Conference Call. All participants will be in a listen-only mode until the question-and-answer session begins. This call is being recorded. If anyone has objections, please disconnect at this time. It is now my pleasure to turn the call over to Mr. Caspar Tudor, Head of Investor Relations.

Caspar TudorHead of Investor Relations

Please go ahead, sir. Thank you, Ryan, and good morning, everyone.

Caspar TudorHead of Investor Relations

Welcome to Waters Corporation's Third Quarter Earnings Call. Joining me today are Dr. Udit Batra, our President and Chief Executive Officer, and Amol Chaubal, our Senior Vice President and Chief Financial Officer. Before we begin, I will cover the cautionary language. In this conference call, we will make various forward-looking statements regarding future events or financial performance. We will provide guidance and commentary on possible future results and potential market and business conditions that may impact Waters over the fourth quarter of 2026, full year 2026, and 2027. These statements are only our present expectations and are subject to risks and uncertainties. Please see the risk factors in our SEC filings and the cautionary language included in this morning's earnings release. During today's call, we will refer to certain non-GAAP financial measures.

Caspar TudorHead of Investor Relations

Reconciliations to the most directly comparable GAAP measures are in our earnings release and the appendix of today's slide presentation. Unless stated otherwise, all organic revenue growth rates are presented on a constant currency basis and are in comparison to the third quarter of 2025. For acquired business revenue, unless stated otherwise, all growth rates are presented on an as-reported basis, covering the current period in comparison to the revenue as reported by BD for the prior year comparable period that predates Waters' ownership. Finally, we do not intend to update our guidance, predictions, or projections, except as part of a regularly scheduled earnings release or as otherwise required by law. On today's call, Udit will open with our key messages and business highlights. Amol will then walk through our financial results and updated guidance, and we will close with your questions.

Caspar TudorHead of Investor Relations

With that, it is my pleasure to turn the call over to Udit.

Udit BatraPresident and CEO

Thank you, Caspar, and good morning, everyone. Let me start by thanking our colleagues around the globe who continue to work with rigor and with speed to accelerate the benefits of pioneering science. We delivered another quarter of exceptional results with outstanding year-over-year and quarter-over-quarter momentum across our divisions. We grew double digits organically, extending our longstanding trend of delivering industry-leading results, with revenue stepping up approximately 5% from the second quarter. In our acquired businesses, we are well ahead of our expected pace of transformation and integration, with underlying growth building as our commercial actions, new product launches, and revenue synergies take hold. New sources of growth are also amplifying our results as improving end markets and rising customer lab activity lifts demand for our products in preclinical and downstream settings.

Udit BatraPresident and CEO

Together, these trends give us a fantastic fourth quarter outlook, with our guidance calling for double-digit growth across both our organic and acquired businesses on a days-adjusted basis. They also drive a $43 million raise to our full-year revenue guidance. In our third quarter, total company as-reported revenue was $1.767 billion, comprising of $871 million of organic revenue and $896 million of Waters Biosciences and Waters Diagnostic Solutions. Organic revenue was 9% as reported and 10% in constant currency, at the high end of our constant currency guidance range, with orders outpacing sales by approximately $20 million. Biosciences and diagnostics grew revenue by 1% on a reported basis, slightly ahead of plan and consistent with our guided seasonality assumptions.

Udit BatraPresident and CEO

Adjusted EPS grew 21% to $4.10, driven by strong top-line momentum, operational excellence, and the cost actions we announced last quarter, which are now flowing through the P&L. Let me now cover these drivers of strength in more detail. Beginning with the Analytical Sciences Division, growth was 8% as reported and 9% in constant currency, led by 12% growth in chemistry, low double-digit growth in instruments, and high single-digit growth in service. Pharma grew double digits, with broad-based strength across ethical pharma, generics, CROs, CDMOs, and biotech, all before reshoring has begun to contribute. Growth was strong in every region, led by over 20% growth in China, mid-teens in India, high single digits in the U.S., and mid-single digits in Europe. Non-pharma grew mid-single digits with broad demand across industrial, food, and environmental testing.

Udit BatraPresident and CEO

The Biosciences Division grew 2% as reported, led by high single-digit growth in both research and clinical reagents. Customer traction for our newly launched FACSDiscover A7 flow cytometer has been strong since its mid-September launch, and we expect it to become a meaningful contributor to instrument growth starting in the fourth quarter. In China, we returned to growth following a low double-digit decline last quarter as localization came online ahead of schedule and new leadership drove better execution. This is the first quarter of positive growth for Biosciences in China in 10 quarters. The Advanced Diagnostics Division grew 2% on a reported basis. The acquired Diagnostic Solutions business was flat on a reported basis as expected. China DRG diluted growth by approximately 200 basis points in the final quarter before it annualizes into the baseline.

Udit BatraPresident and CEO

As we outlined last quarter, we are managing channel inventory to end customer demand compared with last quarter's third quarter build. Excluding both, underlying growth was approximately 5%. Also within the division, the organic Clinical Business Unit grew 17% as reported and 18% in constant currency. We grew double digits across all regions, fueled by test and portfolio expansion in LC-MS diagnostics and due to lead sharing from our acquired molecular diagnostics business. The Materials Sciences Division grew 7% as reported and 9% in constant currency, sustaining the high single-digit growth we returned to last quarter. Growth was led by materials testing for semiconductors and data center build-outs, along with thermal analysis for aerospace and defense. Separately, we saw a broad rebound in China, which grew well into the double digits. Several parts of the portfolio stand out where growth accelerated meaningfully versus the second quarter.

Udit BatraPresident and CEO

In flow reagents, reported growth accelerated 400 basis points to 8% as research reagents grew high single digits, up from low single digits last quarter on stronger commercial execution, improving end markets and pricing. Growth was led by our highly differentiated Horizon Real Dyes, which grew mid-double digits. In chemistry consumables, growth accelerated 200 basis points to 12%. This marks our sixth consecutive quarter of double-digit growth, again led by bioseparations, where MaxPeak Premier Columns grew mid-double digits. Since the second quarter, we have observed a contribution from AI-driven workflows in pharma R&D settings, which has helped sustain double-digit chemistry growth against double-digit comparisons. LC-MS instrument growth accelerated 200 basis points to 10%, or 11% including clinical LC-MS, driven by robust instrument replacement and strong adoption of our new products. Complex biologics spanning bioseparations and bioanalytical characterization is where our capabilities, portfolio, and differentiations show most clearly.

Udit BatraPresident and CEO

This is a result of a deliberate multi-year strategy of entering faster-growing adjacencies in large molecule applications, where our leading solutions continue to outperform the market. The Xevo MRT mass spectrometer is a clear example of our innovation at work, with sales more than tripling year over year. The recent launch of the Xevo MRT P10 system builds on this success by setting a new standard for speed and throughput in omics research. We have also delivered strong clinical mass spec growth throughout the year, marking further success in our LC-MS into diagnostics, high-growth adjacency in hospitals and specialty labs, as well as for DMPK and other pharma clinical workflows. Our position in these labs has been further strengthened by the recent launch of our Xevo TQ Absolute XR IVD instrument, the industry's most sensitive and robust clinical mass spec.

Udit BatraPresident and CEO

Now turning to our acquired businesses, the rapid execution initiatives under our 180-day growth revitalization plan are delivering tangible results, and the benefits are progressively taking hold. On pricing, net price realization scaled to 120 basis points, up from 90 basis points last quarter, giving us further confidence that we will meet or exceed the 150 basis points over the next several quarters. On reagent rental compliance, our dedicated team is now addressing the global opportunity we identified. We expect to begin recapturing low to mid-single digit millions of dollars per quarter beginning in the fourth quarter and further adding to our opportunity ahead. In Biosciences, local manufacturing in China came online ahead of schedule and was a key driver of the geography's return to growth.

Udit BatraPresident and CEO

Looking ahead versus first half levels, local manufacturing, better execution, including faster export license approvals, and DRG annualizing into the baseline should together add about 200 basis points to Biosciences growth over the next several quarters. Together, these actions have driven a clear inflection in growth. Our guidance implies 5% constant currency growth for our acquired businesses in the second half of 2026, with further runway to grow faster as these benefits continue to take hold. In addition, as part of a second phase of execution initiatives, we have now launched a localization initiative for our microbiology portfolio in China, which we expect to further augment growth in the quarters ahead. In parallel, the first full tranche of revenue synergies from our combination is now entering our results.

Udit BatraPresident and CEO

With the BACTEC FXi culture system and the FACSDiscover A7 flow cytometer now launched, service plan attachment rising, and new digital channels beginning to generate incremental sales, the fourth quarter marks the first in which all of these levers contribute together. With this progress, we firmly remain on track to deliver $50 million of revenue synergies in 2026. We're also applying our launch excellence model to our Onclarity HPV self-collection kit launch in molecular diagnostics. This FDA-cleared solution enables individuals to collect their own sample at home, expanding access for the more than 24 million people in the U.S. who are unscreened or under-screened for HPV, the cause of nearly all cervical cancers.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day